期刊文献+

吉西他滨联合DF化疗方案治疗晚期食管癌的临床研究

Clinical Study of Gemcitabine Combined with DF Chemotherapy Regimen in the Treatment of Advanced Esophageal Cancer
下载PDF
导出
摘要 目的:研究吉西他滨联合DF化疗(顺铂+5-氟尿嘧啶)方案治疗晚期食管癌对血清肿瘤标志物、血管新生及预后的影响。方法:选取2021年1月—2022年12月南阳市第一人民医院收治的82例晚期食管癌患者作为研究对象,采用随机数表法将其分为对照组(DF化疗)和观察组(DF化疗+吉西他滨),每组各41例。观察两组患者治疗后的血清肿瘤标志物水平[糖类抗原125(CA125)、糖类抗原19-9(CA19-9)、癌胚抗原(CEA)]、血管新生情况[转化生长因子β1(TGF-β1)、血管内皮生长因子(VEGF)、基质金属蛋白酶9(MMP-9)]。结果:观察组疾病总缓解率(ORR)、疾病总控制率(DCR)均高于对照组,差异有统计学意义(χ^(2)=4.201、4.479,P<0.05);治疗后,观察组CA125、CA9-9、CEA水平均低于对照组,差异有统计学意义(t=10.553、8.804、5.903,P<0.05);治疗后,观察组TGF-β1、VEGF、MMP-9水平均低于对照组,差异有统计学意义(t=8.817、10.741、15.080,P<0.05);两组患者骨髓抑制、肝肾功能异常等Ⅰ~Ⅳ级毒副反应发生率比较,差异无统计学意义(χ^(2)=0.265、0、0.091、0.345、0.064,P>0.05);半年内,观察组复发率低于对照组,差异有统计学意义(χ^(2)=4.205,P<0.05)。结论:吉西他滨联合DF化疗方案治疗晚期食管癌可以提高疗效,降低血清肿瘤标志物水平,减少血管新生,毒副反应可耐受,预后较好。 Objective:To study the effect of gemcitabine combined with DF chemotherapy(cisplatin+5-fluorouracil)on advanced esophageal cancer on serum tumor markers,angiogenesis and prognosis.Methods:82 patients with advanced esophageal cancer hospitalized from January 2021 and December 2022 were selected and divided into the control group(DF chemotherapy)and observation group(DF chemotherapy+gemcitabine)to observe the serum levels of tumor markers[sugar antigen 125(CA 125),sugar antigen 19-9(CA19-9),carcinoembryonic antigen(CEA)],angiogenesis[transforming growth factorβ1(TGF-β1),vascular endothelial growth factor(VEGF),matrix metalloproteinaseenzyme 9(MMP-9)].Results:The total disease response rate(ORR)and total disease control rate(DCR)were higher than the control group(χ^(2)=4.201,4.479;P<0.05).CA125,CA9-9 and CEA levels were lower than the control group(t=10.553,8.804,5.903;P<0.05).TGF-β1,VEGF and MMP-9 were lower than the control group(t=8.817,10.741,15.080;P<0.05).Incidence of classⅠtoⅣtoxic and side effects,such as bone marrow suppression and renal function abnormalities(χ^(2)=0.265,0,0.091,0.345,0.064;P>0.05).The recurrence rate in the observation group was lower than the control group(χ^(2)=4.205,P<0.05).Conclusion:The combination of gemcitabine and DF chemotherapy can improve efficacy in advanced esophageal cancer,reduce serum tumor marker level,reduce angiogenesis and tolerate toxic side effects,and have better prognosis.
作者 侯万聪 尹路 张君 Hou Wancong;Yin Lu;Zhang Jun(The Third Department of Oncology,Nanyang First People’s Hospital,Nanyang,Henan,473000,China)
出处 《黑龙江医学》 2024年第18期2248-2250,共3页 Heilongjiang Medical Journal
关键词 吉西他滨 顺铂+5-氟尿嘧啶化疗方案 食管癌 Gemcitabine DF chemotherapy regimen Esophageal cancer
  • 相关文献

参考文献5

二级参考文献36

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部